Clinical Trial Update: Targeting Interferon Gamma With Emapalumab to Lung Transplant Recipients With Interferon Gamma-high Acute Lung Allograft Dysfunction [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating emapalumab (anti-IFN-γ) for lung transplant recipients with interferon gamma-high acute lung allograft dysfunction; the s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Allograft Dysfunction
• Lung Transplant

Drugs mentioned

• GAMIFANT (emapalumab-lzsg)

Snippet

Sponsor: University of California, San Francisco | Conditions: Lung Transplant | Phase 2 | Status: NOT_YET_RECRUITING